What is Latch Bio?
Latch Bio operates at the intersection of cloud computing and life sciences, providing a sophisticated, no-code platform designed to democratize access to bioinformatics. By enabling scientists to store, transform, and visualize complex datasets through a standard web browser, the company effectively removes the technical barriers that have historically hindered rapid discovery in the biotech sector. Its infrastructure supports a wide array of popular bioinformatics pipelines, positioning Latch Bio as a critical utility for researchers and organizations aiming to accelerate their R&D cycles through digital transformation.
How much funding has Latch Bio raised?
Latch Bio has raised a total of $33M across 2 funding rounds:
Angel/Seed
$5M
Series A
$28M
Angel/Seed (2021): $5M with participation from Haystack, Lux Capital, and General Catalyst
Series A (2022): $28M led by Caffeinated Capital, Coatue, Lux Capital, Haystack, Fifty Years, and Hummingbird Ventures
Key Investors in Latch Bio
General Catalyst
General Catalyst is a prominent venture capital firm that partners with founders to build enduring enterprises by providing deep sector expertise and operational support across technology and healthcare verticals.
Lux Capital
Lux Capital is a New York-based firm specializing in early-stage and growth-stage investments at the intersection of science and technology, with a strong focus on biotechnology and frontier innovation.
Coatue
Coatue Management is a global investment firm that leverages deep market analysis to provide strategic capital to high-growth companies across the public and private equity landscapes.
What's next for Latch Bio?
With the recent influx of capital, Latch Bio is well-positioned to expand its product suite and deepen its integration within the global research ecosystem. The company is expected to focus on enhancing its cloud-based architecture to support larger, more complex datasets while fostering strategic partnerships with academic and commercial laboratories. As the biocomputing landscape matures, Latch Bio's focus on user-centric, scalable infrastructure will likely serve as a key differentiator, enabling the firm to capture significant market share in the rapidly evolving deep tech and life sciences sectors.
See full Latch Bio company page
